Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nipro Confirms Coronavirus Infection Case at Niigata Branch
March 12, 2020
- Shionogi Wins Osaka Tax Suit over ViiV Deal
March 12, 2020
- Santen Calls Off Development of wAMD Treatment after PIIa Fails
March 12, 2020
- Kowa’s Glaucoma Med Glanatec Approved in Singapore
March 12, 2020
- Drug Makers Calling Off Welcoming Ceremonies for New Hires over Coronavirus
March 11, 2020
- Relugolix Combo Tablet Filed in EU for Uterine Fibroids
March 11, 2020
- Janssen Files for Darzalex in Japan for Combo Therapy with Carfilzomib, Dexamethasone
March 11, 2020
- Medipal Forms Capital and Business Alliance with Cardiac Regenerative Medicine Startup
March 11, 2020
- Pfizer Most Affected by G1 Rule, 8 Off-Patent APIs Go into This Category: Jiho Survey
March 10, 2020
- Japan’s 2020 Price Revision Hits Major Drugs with Double-Digit Slashes: Top 5 Product Survey
March 10, 2020
- Takeda Continued Takecab Push for Hospital Doctors in January: Impact Track
March 10, 2020
- Biogen’s Coronavirus Woes Grow, Japan Unit Says Its Staffers Attended Boston Confab Too
March 10, 2020
- Shionogi Confirms Novel Coronavirus Infection at Its Group Company
March 10, 2020
- Aducanumab “on Track” for FDA Filing: Eisai CEO
March 9, 2020
- FTC Hits Torii with Cease, Desist, and Surcharge Payment Order over Price-Fixing for Calvan
March 9, 2020
- Japan’s Big 3 Generic Makers See 12.2% Price Cut vs. FY2018: Jiho Poll
March 9, 2020
- FDA Accepts Vibegron for Review; Target Date Set for Dec. 26
March 9, 2020
- Shionogi Boosts Stake in Tetra under Alzheimer's Deal; Buyout on the Cards
March 9, 2020
- Japan Ethical Drug Sales Down 1.2% in January: Crecon
March 9, 2020
- Large-Scale Clinical Data Confirms Efficacy and Safety of Switch to Vemlidy for Hep B: Gilead
March 9, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…